PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia
Status:
Completed
Trial end date:
2019-10-14
Target enrollment:
Participant gender:
Summary
This study assess pharmacokinetics and safety of multi-administration of Aripiprazole IM
Depot formulation at doses of 400mg in patients with schizophrenia.